DavidMcCallMD

Pediatric Hematology & Oncology • Houston, TX

Pediatric Hematologic Oncology

Assistant Professor

Join to view full profile

Dr. McCall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McCall's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Medical College of Georgia at Augusta UniversityClass of 2014

Certifications & Licensure

WA State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2023 - 2025
TN State Medical License 2023 - 2025
TX State Medical License 2017 - 2025
AL State Medical License 2016 - 2024
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology
Join now to see all

Clinical Trials

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2022 Oct 05
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Impact Of Muscle Vibration On Gait Control Start of enrollment: 2021 Oct 04
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia Start of enrollment: 2023 Jul 14
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias Start of enrollment: 2024 Oct 31
Not yet recruiting
Phase 1
Roles: Principal Investigator, Contact
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias Start of enrollment: 2024 Dec 31
Not yet recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia.
Amber Gibson, Samantha Dickson, David McCall, Miriam Garcia, Jeremy Connors
Pediatric Blood & Cancer. 2024-11-01
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the internatio...
Branko Cuglievan, Hagop Kantarjian, Jeffrey E Rubnitz, Todd M Cooper, C Michel Zwaan
Leukemia. 2024-10-01
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis.
David McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, Shehab Fareed Mohamed, Anish Patnaik
Leukemia Research. 2024-09-01

Press Mentions

ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory DisorderDecember 9th, 2024